XML 44 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)
3 Months Ended
Oct. 03, 2018
USD ($)
obligation
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
May 31, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Development, regulatory and sales milestones payments   $ 4,100,000,000        
Revenues   62,546,000 $ 27,439,000      
Deferred revenue   66,281,000   $ 74,099,000    
Collaboration and License agreements            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Initial transaction price $ 252,700,000          
JJDC | Collaboration and License agreements            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Upfront payment 175,000,000          
JJDC | Common Stock Purchase Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Proceeds from the issuance of common stock 75,000,000          
Janssen            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Milestone payment 73,000,000          
Janssen | License Agreement | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Development, regulatory and sales milestones payments 800,000,000          
Janssen | Collaboration Agreement | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Development, regulatory and sales milestones payments 600,000,000          
Janssen | JNJ-3989 (ARO-HBV) Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Milestone payment $ 25,000,000          
Number of distinct performance obligations | obligation 1          
Contract assets   0        
Deferred revenue   0        
Janssen | JNJ-75220795 (ARO-JNJ1)            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Milestone payment         $ 10,000,000 $ 10,000,000
Revenues   0 $ 0      
Contract assets   0        
Deferred revenue   $ 0